Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Trent Wang is an Associate Professor of Clinical Medicine within the Division of Transplantation and Cellular Therapy. Since joining Sylvester Comprehensive Cancer Center, his clinical focus has been treating patients with hematologic cancers who require allogeneic hematopoietic stem cell transplantation and other cellular therapies.
Dr. Wang's research focuses on complications of allogeneic hematopoietic stem cell transplantation, including conducting interventional, behavioral and retrospective studies of graft-versus-host disease, infectious transplant complications, and transplant survivorship. Dr. Wang also studies the outcomes of immune effector cell therapies such as CAR-T cells for various oncologic indications. -
Education & Training
Education
Post Graduate Training
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Cell Therapy Appears Safe and Effective for Lymphoma in Remission
Sylvester K12 Symposium Brings Together Prior and New Award Winners
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 11 clinical trials.
-
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Activity, and Efficacy of SNDX- 6352 in Subjects With Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Prior Therapy
- Principal Investigator: Trent Wang
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
- Principal Investigator: Trent Wang
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)
- Principal Investigator: Trent Wang
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
- Principal Investigator: Trent Wang
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
- Principal Investigator: Trent Wang
- Study Phase: Phase 1
- Enrollment Status: Closed
-
Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
- Principal Investigator: Trent Wang
- Study Phase: N/A
- Enrollment Status: Closed
-
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
- Principal Investigator: Trent Wang
- Study Phase: Phase 2
- Enrollment Status: Closed
-
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
- Principal Investigator: Trent Wang
- Study Phase: Phase 2
- Enrollment Status: Open
-
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Principal Investigator: Trent Wang
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
The purpose of this trial is to treat a single patient with an out of specification dose of Amtagvi. Patient has exhausted all other treatment options.
- Principal Investigator: Trent Wang
- Study Phase: N/A
- Enrollment Status: Closed
-
The purpose of this study is to see whether giving participants a combination treatment of axatilimab and extracorporeal photopheresis (ECP) is effective against cGVHD.
- Principal Investigator: Trent Wang
- Study Phase: Phase II
- Enrollment Status: Open